The Editorial Advisory Board of Pharma Focus Asia comprises of industry thought leaders with wide-ranging experience, expertise and significant contributions to the pharmaceutical industry. We thank and acknowledge our Editorial Advisory Board members' willingness to share their expertise and industry insights with us to offer our readers the most appropriate editorials covering issues of paramount importance to the industry.
Pramod Kashid has more than 17 years’ experience in the clinical research industry. Dr Kashid is currently working with a global CRO ( Medpace) as a Senior Director, Clinical Trial Management. He has experience in leading clinical drug development projects in Oncology, Cardiology, and infectious disease therapeutic areas in Asia Pacific region. He has expertise in strategic drug development planning and cross-functional stakeholder management, audit, and inspection management.
Stella Stergiopoulos is Director, Health Economics and Outcomes Research, EQRx. She managed multi-sponsored and grant funded research projects at Tufts CSDD. She has experience conducting research on pharmaceutical industry practices and trends affecting pharmaceutical outsourcing practices, cycle time metrics, resource management, and protocol design. She has been a presenter at conferences and has published in peer-reviewed and trade journals..
Sanjoy Ray has a PhD in Protein Engineering from Imperial College, London and held a postdoctoral research fellowship in Structural Biophysics at Harvard University. He has 14 years of IT experience, enabling scientific high-performance computing at Boston's Children's Hospital and the Whitehead Institute, MIT. After leading an information technology innovation group at Merck & Co., Inc, he is currently working as a Senior Director, Oncology & Immunology TA R&D Business Technology in Janssen Pharmaceuticals.
Rustom Mody, Ph.D. has over 19 years of experience in the biopharmaceutical and vaccine industry. He is currently the Sr. Vice President and Head R&D (Biologics) at SUN PHARMA. He has broad experience in the areas of vaccines and biosimilars such as development of process, analytical test methods, scale-up, manufacturing, formulation and characterization. He has interfaced with various National / International regulatory agencies and has been an external expert for product monographs for Indian and US pharmacopoeia.
Phil Kaminsky is currently a Senior Principal Research Scientist at Amazon and leads the Middle Mile Marketplace Science team. He is also Earl J. Isaac Professor in the Science and Analysis of Decision Making at the University of California at Berkeley.
Neil J Campbell is currently Chairman and CEO for Mosaigen™, Inc., a global Life Science development corporation, located in Rockville, Maryland and Partner with Endeavour Capital in Asia. During his career, he has successfully developed and introduced over 200 products in healthcare, life sciences and information technology. He earned his MBA and MA in Management Systems from Webster University in Saint Louis, Missouri and his BS-BA from Norwich University in New England.
Laurence Flint is a board certified paediatrician and Director, Vaccine Clinical Research and Development at Pfizer. Laurence holds a BS in Biology and English from the University of Scranton, an MS in Biology and an MBA from Fairleigh Dickinson University, and a medical degree from UMDNJ-New Jersey Medical School.
Kenneth Kaitin is Professor of Medicine and Senior Fellow at the Tufts Center for the Study of Drug Development. He previously served as the group’s Director for 23 years. He is also Advisory Professor at Shanghai Medical College at Fudan University, and he serves on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel.
Georg C Terstappen is a biologist by training with a PhD in natural sciences - has 30 years of experience in pharma R&D with a focus on CNS diseases. In this regard he worked in leading positions in major international pharmaceutical companies including Bayer, GlaxoWellcome, GlaxoSmithKline, Abbott and AbbVie, and in the biotech industry where he was co-founder of a ‘start-up’ drug discovery company (Siena Biotech) and CSO of OxStem, a spin-out company of the University of Oxford. He is currently an Executive Vice President, Drug Discovery at Cambrian Biopharma.
Frank Jaeger is currently Chief Commercial Officer, Clarus Therapeutics. Frank has held cross-disciplinary positions previously in Clinical Research, Medical Services, and Marketing.